Pharmadrug(TSE:PHRX)
CA$0.010.00 (0.00%)
TSE:PHRX
Pharmadrug financials statements
CA$0.01
At close:0.00 (0.00%)
Want to see TSE:PHRX full AI Analyst Report?
Pharmadrug (PHRX) Ratios
34 Followers
Pharmadrug Ratios
TSE:PHRX's free cash flow for Q2 2026 was C$-25.71K. For the 2026 fiscal year, TSE:PHRX's free cash flow was increased by C$0.00 and operating cash flow was C$-25.71K. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.02 | 0.08 | 0.22 | 0.61 | 3.32 |
| Quick Ratio | 0.02 | 0.08 | 0.22 | 0.61 | 3.00 |
| Cash Ratio | 0.01 | 0.04 | 0.15 | 0.00 | 2.00 |
| Solvency Ratio | -0.15 | -0.38 | -4.94 | -2.70 | -2.21 |
| Operating Cash Flow Ratio | -0.05 | -0.39 | -0.25 | -1.03 | -8.60 |
| Short-Term Operating Cash Flow Coverage | -0.06 | -0.56 | -0.38 | -1.59 | -96.67 |
| Net Current Asset Value | C$ -2.17M | C$ -1.81M | C$ -2.07M | C$ -1.94M | C$ -1.06M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 2.75 | 1.90 | 1.47 | 0.12 | 0.04 |
| Debt-to-Equity Ratio | -0.86 | -0.96 | -1.04 | 0.16 | 0.05 |
| Debt-to-Capital Ratio | -6.21 | -24.81 | 28.43 | 0.14 | 0.05 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 |
| Financial Leverage Ratio | -0.31 | -0.51 | -0.70 | 1.37 | 1.16 |
| Debt Service Coverage Ratio | -0.04 | -0.34 | -0.15 | -1.31 | -40.93 |
| Interest Coverage Ratio | -0.73 | -2.44 | -3.99 | -10.88 | -46.50 |
| Debt to Market Cap | 0.94 | 1.30 | 0.63 | 0.27 | 0.07 |
| Interest Debt Per Share | 0.02 | 0.02 | 0.04 | 0.03 | 0.02 |
| Net Debt to EBITDA | -20.78 | -2.32 | -1.02 | -0.60 | 0.02 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | -30.75% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | -60265.37% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | -60037.10% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | -39891.57% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | -61121.42% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | -83806.53% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | -61121.42% |
| Net Income Per EBT | 88.64% | 90.85% | 92.49% | 272.77% | 137.11% |
| EBT Per EBIT | 191.43% | 130.58% | 1069.14% | 133.91% | 153.22% |
| Return on Assets (ROA) | -69.50% | -111.44% | -1100.83% | -73.28% | -30.09% |
| Return on Equity (ROE) | 21.74% | 56.53% | 774.40% | -100.46% | -34.83% |
| Return on Capital Employed (ROCE) | 16.59% | 53.74% | 91.08% | -24.51% | -14.68% |
| Return on Invested Capital (ROIC) | -144.27% | -639.06% | -412.09% | -20.18% | -14.62% |
| Return on Tangible Assets | -1030.47% | -539.26% | -2214.11% | -662.40% | -346.88% |
| Earnings Yield | -23.64% | -76.33% | -467.39% | -168.75% | -50.68% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 |
| Payables Turnover | 0.13 | 0.14 | 0.06 | 0.00 | 0.04 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2869.90 | -2688.03 | -6259.31 | -84724.52 | 668.70 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 4370.52 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 6215.79 |
| Days of Payables Outstanding | 2869.90 | 2688.03 | 6259.31 | 84724.52 | 9917.61 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 10586.32 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.00 | -0.01 | -0.01 | -0.05 | -0.09 |
| Free Cash Flow Per Share | -0.00 | -0.01 | -0.01 | -0.05 | -0.09 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -63.18 | 0.00 | 0.00 | -96.57 |
| Capital Expenditure Coverage Ratio | 0.00 | -63.18 | 0.00 | 0.00 | -96.57 |
| Operating Cash Flow Coverage Ratio | -0.06 | -0.56 | -0.38 | -1.59 | -4.76 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -588.57 |
| Free Cash Flow Yield | -5.40% | -73.95% | -23.79% | -42.91% | -35.96% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -4.17 | -1.32 | -0.21 | -0.59 | -1.97 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 1653.79 |
| Price-to-Book (P/B) Ratio | -0.92 | -0.74 | -1.66 | 0.60 | 0.69 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -18.53 | -1.35 | -4.20 | -2.33 | -2.78 |
| Price-to-Operating Cash Flow Ratio | -18.53 | -1.37 | -4.20 | -2.33 | -2.81 |
| Price-to-Earnings Growth (PEG) Ratio | 0.08 | 0.01 | -0.00 | -0.07 | 0.04 |
| Enterprise Value Multiple | -43.31 | -4.21 | -3.13 | -2.85 | -2.73 |
| Enterprise Value | 3.12M | 2.31M | 4.18M | 6.67M | 11.50M |
| EV to EBITDA | -43.31 | -4.21 | -3.13 | -2.85 | -2.73 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 1640.72 |
| EV to Free Cash Flow | -35.62 | -3.01 | -6.22 | -2.96 | -2.76 |
| EV to Operating Cash Flow | -35.62 | -3.06 | -6.22 | -2.96 | -2.79 |
| Tangible Book Value Per Share | -0.02 | -0.02 | -0.04 | -0.04 | -0.02 |
| Shareholders’ Equity Per Share | -0.02 | -0.01 | -0.03 | 0.18 | 0.36 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.07 | 0.06 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.00 | -0.01 | -0.23 | -0.18 | -0.12 |
| Tax Burden | 0.89 | 0.91 | 0.92 | 2.73 | 1.37 |
| Interest Burden | 3.54 | 1.46 | 10.49 | 1.38 | 1.01 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 79.01 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 317.39 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 85.57 |
| Income Quality | 0.23 | 0.87 | 0.05 | 0.74 | 0.70 |
Currency in CAD

